Volume : 09, Issue : 10, October – 2022

Title:

81.TYPES OF DIABETES MELLITUS INTERLINKED WITH CANCER, OTHER DISEASES, AND COMPLICATIONS WITH OR WITHOUT CANCER
‬

Authors :

Sana Zulfiqar, Rida Zareen Hassan, Mareena Khan

Abstract :

Cancer and type 2 diabetes are both common illnesses around the globe. Diabetes patients clearly have a much higher incidence of cancer. According to epidemiologic research, people with diabetes are much more likely to develop common malignancies such as gastric, pancreatic, urinary tract, breast, liver, colorectal, and female reproductive cancers. Patients with diabetes have a somewhat higher risk of dying from cancer than those without the disease. Though the underlying processes of this putative relationship have not yet been completely explored, there is mounting evidence that some malignancies and diabetes are related. Insulin is a powerful growth agent that stimulates cell division and the development of cancer either directly or indirectly via insulin-like growth factor 1. (IGF1). IGF binding protein-1 is inhibited by hyperinsulinemia, increasing the bioactivity of IGF-1. A more plausible and believable reason for the development of cancer is hyperglycemia. High glucose levels may encourage the development of cancer cells both directly and indirectly. Additionally, persistent inflammation is seen as a characteristic of cancer development. The many medications used to manage diabetes seem to alter the cancer risk. To improve the prognosis of diabetic cancer patients, early cancer detection screenings and proper cancer therapy are crucial. The links between diabetes and common malignancies are outlined in this research along with potential explanations and practical consequences for medical practice.
Keywords: Cancer, Diabetes, Association, Mechanism

Cite This Article:

References:

1. Ottaiano, A., Circelli, L., Santorsola, M., Savarese, G., Fontanella, D., Gigantino, V., … & Caraglia, M. (2022). Metastatic colorectal cancer and type 2 diabetes: prognostic and genetic interactions. Molecular oncology, 16(2), 319-332.
2. Sousa, A. P., Costa, R., Alves, M. G., Soares, R., Baylina, P., & Fernandes, R. (2022). The Impact of Metabolic Syndrome and Type 2 Diabetes Mellitus on Prostate Cancer. Frontiers in Cell and Developmental Biology, 10, 843458-843458.
3. Iacobini, C., Vitale, M., Haxhi, J., Pesce, C., Pugliese, G., & Menini, S. (2022). Food-Related Carbonyl Stress in Cardiometabolic and Cancer Risk Linked to Unhealthy Modern Diet. Nutrients, 14(5), 1061.
4. Pinheiro, L. C., Soroka, O., Kern, L. M., Higgason, N., Leonard, J. P., & Safford, M. M. (2022). Racial disparities in diabetes care among incident breast, prostate, and colorectal cancer survivors: a seer Medicare study. Journal of Cancer Survivorship, 16(1), 52-60.
5. Singh-Makkar, S., Pandav, K., Hathaway III, D., Paul, T., & Youssef, P. (2022). Multidimensional mechanisms of metformin in cancer treatment. Tumori Journal, 108(2), 111-118.
6. Koroglu Aydın, P., Karabulut‐Bulan, O., Bugan, I., Turkyilmaz, I. B., Altun, S., & Yanardag, R. (2022). The protective effect of metformin against testicular damage in diabetes and prostate cancer model. Cell Biochemistry and Function, 40(1), 60-70.
7. Mao, D., Lau, E. S., Wu, H., Yang, A., Shi, M., Fan, B., … & Chan, J. C. (2022). Risk associations of long-term HbA1c variability and obesity on cancer events and cancer-specific death in 15,286 patients with diabetes-A prospective cohort study. The Lancet Regional Health-Western Pacific, 18, 100315.
8. Morrison, A. J. (2022). Cancer cell metabolism connects epigenetic modifications to transcriptional regulation. The FEBS Journal, 289(5), 1302-1314.
9. Taylor, A., Siddiqui, M. K., Ambery, P., Armisen, J., Challis, B. G., Haefliger, C., … & Palmer, C. N. (2022). Metabolic dysfunction-related liver disease as a risk factor for cancer. BMJ open gastroenterology, 9(1), e000817.
10. Sargazi, S., Ravanbakhsh, M., Nia, M. H., Mirinejad, S., Sheervalilou, R., Majidpour, M., … & Saravani, R. (2022). Association of polymorphisms within HOX transcript antisense RNA (HOTAIR) with type 2 diabetes mellitus and laboratory characteristics: a preliminary case-control study. Disease Markers, 2022.
11. Strongman, H., Gadd, S., Matthews, A. A., Mansfield, K. E., Stanway, S., Lyon, A. R., … & Bhaskaran, K. (2022). Does cardiovascular mortality overtake cancer mortality during cancer survivorship? An English retrospective cohort study. Cardio Oncology, 4(1), 113-123.
12. Ashique, S., Upadhyay, A., Kumar, N., Chauhan, S., & Mishra, N. (2022). Metabolic syndromes responsible for cervical cancer and advancement of nanocarriers for efficient targeted drug delivery-A review. Advances in Cancer Biology-Metastasis, 100041.
13. Larson, A. E., Angier, H., Suchocki, A., Voss, R. W., Marino, M., Warren, N., & Huguet, N. (2022). Primary and mental health service use in community health center patients before and after cancer diagnosis. Cancer Medicine.
14. Freedman, L. S., Agay, N., Farmer, R., Murad, H., Olmer, L., & Dankner, R. (2022). Metformin treatment among men with diabetes and the risk of prostate cancer: a population-based historical cohort study. American journal of epidemiology, 191(4), 626-635.
15. Srinivasan, M., Arzoun, H., Gk, L. B., & Thangaraj, S. R. (2022). A Systematic Review: Does Insulin Resistance Affect the Risk and Survival Outcome of Breast Cancer in Women?. Cureus, 14(1).
16. Sjöholm, K., Carlsson, L. M., Svensson, P. A., Andersson-Assarsson, J. C., Kristensson, F., Jacobson, P., … & Taube, M. (2022). Association of bariatric surgery with cancer incidence in patients with obesity and diabetes: long-term results from the Swedish Obese Subjects study. Diabetes care, 45(2), 444-450.
17. Liu, X. H., Qi, L. W., Alolga, R. N., & Liu, Q. (2022). Implication of the hepatokine, fibrinogen-like protein 1 in liver diseases, metabolic disorders and cancer: The need to harness its full potential. International Journal of Biological Sciences, 18(1), 292.
18. Ugai, T., Sasamoto, N., Lee, H. Y., Ando, M., Song, M., Tamimi, R. M., … & Ogino, S. (2022). Is early-onset cancer an emerging global epidemic? Current evidence and future implications. Nature Reviews Clinical Oncology, 19(10), 656-673.
19. Xiu, W., Huang, Y., Li, Y., Yu, M., & Gong, Y. (2022). Comorbidities and mortality risk among extensive-stage small-cell lung cancer patients in mainland China: impacts of hypertension, type 2 diabetes mellitus, and chronic hepatitis B virus infection. Anti-Cancer Drugs, 33(1), 80.
20. Archangelidi, O., Cullinan, P., Simmonds, N. J., Mentzakis, E., Peckham, D., Bilton, D., & Carr, S. B. (2022). Incidence and risk factors of cancer in individuals with cystic fibrosis in the UK; a case-control study. Journal of Cystic Fibrosis, 21(2), 302-308.
21. Hasan, M. I., Hossain, M. A., Bhuiyan, P., Miah, M. S., & Rahman, M. H. (2022). A system biology approach to determine therapeutic targets by identifying molecular mechanisms and key pathways for type 2 diabetes that are linked to the development of tuberculosis and rheumatoid arthritis. Life Sciences, 297, 120483.
22. Rasheed, H., Shehzad, M., Rabail, R., Kowalczewski, P. Ł., Kidoń, M., Jeżowski, P., … & Aadil, R. M. (2022). Delving into the nutraceutical benefits of purple carrot against metabolic syndrome and cancer: A review. Applied Sciences, 12(6), 3170.
23. Shan, Z., Fa, W. H., Tian, C. R., Yuan, C. S., & Jie, N. (2022). Mitophagy and mitochondrial dynamics in type 2 diabetes mellitus treatment. Aging (Albany NY), 14(6), 2902.
24. Pearson-Stuttard, J., Cheng, Y. J., Bennett, J., Vamos, E. P., Zhou, B., Valabhji, J., … & Gregg, E. W. (2022). Trends in leading causes of hospitalisation of adults with diabetes in England from 2003 to 2018: an epidemiological analysis of linked primary care records. The Lancet Diabetes & Endocrinology, 10(1), 46-57.
25. Migliaccio, S., Di Nisio, A., Magno, S., Romano, F., Barrea, L., Colao, A. M., … & Savastano, S. (2022). Vitamin D deficiency: a potential risk factor for cancer in obesity?. International Journal of Obesity, 46(4), 707-717.